The respondents, from 95 countries and with interests in 73 specialties, discussed the performance of top pharmaceutical companies across key factors that influence corporate reputation.
Today, the organization PatientView released the 7th edition of its Corporate Reputation of Pharma report. The report is based on the findings of a survey conducted from November 2017 to February 2018 that explored the views of 1330 patient groups worldwide on the reputation of the pharmaceutical industry.
The respondents, from 95 countries and with interests in 73 specialties, discussed the performance of top pharmaceutical companies across key factors that influence corporate reputation. The factors evaluated in the report included effective patient-centered strategies, providing high-quality patient information, ensuring safety, supplying useful and high-quality products, being transparent about pricing, sharing results of clinical trials, disclosing funding, acting with integrity, and engaging patients, among others.
The report found that 43% of patient groups that responded to the survey thought the pharmaceutical industry had an “excellent” or “good” corporate reputation in 2017, compared with 38% the previous year.
The groups also rated pharma as having improved its performance during 2016 in 3 areas:
However, patients’ view of pharma was more negative in some other key respects. For example, 48% of patient groups surveyed in 2017 believed pharma was “excellent” or “good” at being innovative, which was down from 59% in 2016, and 57% of patient groups saw pharma as “excellent” or “good” at producing high-quality products, which was down from 64% in 2016. Notably, the most recent 2017 data show the lowest-reported percentage of groups who believed in pharma’s ability to manufacture high-quality products since 2011.
The 46 pharmaceutical companies that were evaluated included biosimilar developers Amgen, Boehringer Ingelheim, Gedeon Richter, Merck, Novartis, Pfizer, and Teva, among others.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).